Appendiceal Neuroendocrine Tumor

MONDO:0015066 Pathograph 7 Show in embeddings browser neuroendocrine tumor appendix cancer

Appendiceal neuroendocrine tumors (appendiceal NETs) are well-differentiated epithelial neuroendocrine neoplasms of the vermiform appendix that are often detected incidentally in appendectomy specimens. They are heterogeneous rather than uniformly serotonin-producing: a 135-tumor series classified 56% as enterochromaffin (EC)-cell tumors, 27% as L-cell tumors, and 17% as mixed tumors. Most localized tumors are indolent, but tumor size, invasion, and Ki67-based grade inform risk assessment. Appendectomy is sufficient for tumors smaller than 1 cm and, after complete resection, for many tumors measuring 1-2 cm; routine completion right hemicolectomy has not shown a survival advantage in the 1-2 cm group. Serotonin-directed biochemistry and carcinoid-syndrome assumptions apply only to the serotonin-producing branch. Goblet cell adenocarcinoma is a distinct appendiceal epithelial malignancy, not an appendiceal NET subtype.

Ask OpenScientist

Ask a research question about Appendiceal Neuroendocrine Tumor. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
2
Histopath.
1
Phenotypes
2
Gaps
7
Pathograph
4
Medical Actions
1
Differentials
1
Deep Research
?

Discussions and Knowledge Gaps

2
Does EC-cell, L-cell, or mixed-cell differentiation independently predict clinically meaningful recurrence or survival after adjustment for tumor size, grade, and invasion?
KNOWLEDGE GAP OPEN gap_appendiceal_net_cell_type_prognosis
Attached to
pathophysiology#EC-, L-, and Mixed-Cell Tumor Differentiation pathophysiology#Tumor Growth and Tissue Invasion
One retrospective 135-tumor series found strong clinicopathologic differences by cell phenotype, but broader validation is needed before cell typing can be treated as an independent management classifier.
Show evidence (1 reference)
PMID:38833137 SUPPORT Human Clinical
"Tumor type correlated with pT stage and the only patient with distant metastatic disease in this series had an EC-cell tumor."
The single retrospective series motivates, but does not resolve, independent prognostic validation of cell type.
Which patients with completely resected 1-2 cm appendiceal NETs benefit from completion right hemicolectomy or structured long-term surveillance?
CONTROVERSY OPEN controversy_appendiceal_net_surgery_and_follow_up
Attached to
treatments#Appendectomy treatments#Selected Completion Right Hemicolectomy treatments#Selective Post-Treatment Surveillance
Long-follow-up cohorts find no survival advantage from routine hemicolectomy in completely resected 1-2 cm tumors, yet the optimal interpretation of nodal disease and the design and duration of follow-up remain unsettled.
Show evidence (2 references)
PMID:38168835 SUPPORT Other
"Future studies should address the prognostic impact of lymph node metastases and the optimal design and duration of follow-up."
The review directly identifies the unresolved nodal-prognosis and follow-up questions.
PMID:36640790 SUPPORT Human Clinical
"Overall survival was similar between patients with appendectomy and right-sided hemicolectomy"
The pooled cohort supplies the central comparative evidence behind surgical de-escalation in this group.
⚙

Pathophysiology

5
Appendiceal Enteroendocrine-Cell Neoplasia
A well-differentiated epithelial neuroendocrine neoplasm develops in the appendiceal enteroendocrine-cell compartment. This disease-level initiating node does not assume that every tumor has EC-cell differentiation or serotonin production.
enteroendocrine cell CL:0000164 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves enteroendocrine cell (CL:0000164). CL:0000164 is a cell type from the Cell Ontology.
cell population proliferation GO:0008283 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell population proliferation (GO:0008283). GO:0008283 is a biological process from the Gene Ontology. ↑ INCREASED
vermiform appendix UBERON:0001154 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in vermiform appendix (UBERON:0001154). UBERON:0001154 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
EC-, L-, and Mixed-Cell Tumor Differentiation Appendiceal NETs differentiate into at least three immunophenotypic cell-type patterns.
Tumor Growth and Tissue Invasion Neoplastic outgrowth produces a measurable appendiceal tumor that can extend through the appendiceal wall and into the mesoappendix.
Appendiceal Neuroendocrine Tumor The appendiceal neuroendocrine neoplasm is the defining pathologic phenotype.
Show evidence (1 reference)
PMID:38833137 SUPPORT Human Clinical
"Appendiceal neuroendocrine tumors (NETs) are common and often are identified as incidental lesions at the time of appendectomy."
This appendiceal pathology series establishes the organ-specific neuroendocrine neoplasm studied by this node.
EC-, L-, and Mixed-Cell Tumor Differentiation
Appendiceal NETs show EC-cell, L-cell, or mixed immunophenotypic differentiation. In the available 135-tumor retrospective series, EC-cell tumors were the largest group but were not universal; L-cell tumors formed more than one quarter of cases.
enteroendocrine cell CL:0000164 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves enteroendocrine cell (CL:0000164). CL:0000164 is a cell type from the Cell Ontology.
cell differentiation GO:0030154 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal cell differentiation (GO:0030154). GO:0030154 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Serotonin-Producing EC-Cell Branch EC-cell differentiation defines the serotonin-producing branch; mixed tumors can also express serotonin.
Tumor Growth and Tissue Invasion Cell phenotype was associated with size and invasion in one retrospective series, with EC-cell tumors showing the greatest and mixed tumors intermediate involvement.
Show evidence (1 reference)
PMID:38833137 SUPPORT Human Clinical
"Our study confirms that appendiceal NETs are not a homogeneous tumor population. There are at least three types of appendiceal NET, including EC-cell, L-cell, and mixed tumors."
The series directly establishes cell-type heterogeneity within appendiceal NETs.
Serotonin-Producing EC-Cell Branch
EC-cell tumors, and the serotonin-expressing component of mixed tumors, retain a serotonin-producing phenotype. This branch is explicitly conditional and must not be generalized to L-cell tumors or to every appendiceal NET.
type EC enteroendocrine cell CL:0000577 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves type EC enteroendocrine cell (CL:0000577). CL:0000577 is a cell type from the Cell Ontology.
serotonin biosynthetic process GO:0042427 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased serotonin biosynthetic process (GO:0042427). GO:0042427 is a biological process from the Gene Ontology. ↑ INCREASED serotonin secretion GO:0001820 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased serotonin secretion (GO:0001820). GO:0001820 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (1 reference)
PMID:38833137 SUPPORT Human Clinical
"This information is important for surveillance of patients, as monitoring urinary 5HIAA levels is only appropriate for patients with serotonin-producing tumors, whereas measurement of GLPs and/or PP is more appropriate for patients with L-cell tumors."
The disease-specific series restricts serotonin-metabolite monitoring to the serotonin-producing tumor branch and identifies a different biochemical program for L-cell tumors.
Tumor Growth and Tissue Invasion
Increasing tumor size and extension into the serosa or mesoappendix mark a more advanced local lesion. Size is associated with nodal disease, but small tumors confined to the appendix are overwhelmingly indolent.
cell population proliferation GO:0008283 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell population proliferation (GO:0008283). GO:0008283 is a biological process from the Gene Ontology. ↑ INCREASED
vermiform appendix UBERON:0001154 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in vermiform appendix (UBERON:0001154). UBERON:0001154 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Regional Nodal and Rare Distant Spread Larger and invasive tumors have a higher observed probability of regional nodal involvement, although the biological intermediates and prognostic importance of nodal disease remain incompletely resolved.
Show evidence (1 reference)
PMID:33754384 SUPPORT Human Clinical
"Increasing tumour size was associated with an increased risk of nodal disease"
This pathology cohort directly supports tumor size as a clinical risk correlate for nodal involvement.
Regional Nodal and Rare Distant Spread
A minority of appendiceal NETs involve regional lymph nodes, whereas distant metastasis and tumor-related mortality are rare in contemporary long-term cohorts. The clinical importance of microscopic regional nodal disease is disputed.
Show evidence (2 references)
PMID:36640790 SUPPORT Human Clinical
"Regional lymph node metastases were found in 22 (20%) of 112 patients with right-sided hemicolectomy with available data."
The pooled cohort documents regional nodal involvement in resected 1-2 cm tumors.
PMID:36640790 SUPPORT Human Clinical
"All metastases were diagnosed synchronously with no tumour-related deaths during follow-up."
The same long-follow-up cohort supports the rarity and limited mortality impact of distant spread in this size-defined population.
✶

Histopathology

2
Well-Differentiated Appendiceal Neuroendocrine Tumor
The defining microscopic lesion is a well-differentiated epithelial neuroendocrine tumor in the appendix. Tumor size, depth of invasion, and Ki67 proliferation index are recorded for risk stratification; G1 and G2 are grades, not separate disease subtypes in this entry.
Show evidence (1 reference)
PMID:38833137 SUPPORT Human Clinical
"The guidelines for management are based on tumor size, degree of invasion, and the Ki67 proliferation index."
The appendiceal pathology series directly supports the core histopathologic risk variables.
EC-, L-, and Mixed-Cell Immunophenotypes
Immunohistochemistry for serotonin and L-cell-associated markers can resolve EC-cell, L-cell, and mixed appendiceal NET patterns. This is a tumor-cell classification within appendiceal NET, not a claim that each pattern is yet a validated independent clinical subtype.
Show evidence (1 reference)
PMID:38833137 SUPPORT Human Clinical
"We analyzed the expression of biomarkers including CDX2, SATB2, PSAP, serotonin, glucagon (that detects GLPs), PYY, and pancreatic polypeptide (PP) and correlated the results with clinicopathologic parameters."
The series directly describes the immunohistochemical marker panel used for tumor-cell classification.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Appendiceal Neuroendocrine Tumor Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

1
Appendiceal Neuroendocrine Tumor OBLIGATE Neoplastic HP:0100570 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Carcinoid tumor (HP:0100570). HP:0100570 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33754384 SUPPORT Human Clinical
"Appendiceal well-differentiated neuroendocrine tumours (NETs) are usually incidental and clinically benign."
This cohort directly supports the defining tumor phenotype and its usually incidental, indolent presentation.
💊

Medical Actions

4
Appendectomy
Category: Therapeutic Action: appendectomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is appendectomy (NCIT:C51687). NCIT:C51687 is a clinical intervention from the NCI Thesaurus. Ontology label: Appendectomy NCIT:C51687
Simple appendectomy is sufficient for tumors smaller than 1 cm. After complete primary-tumor resection, long-term pooled data also support appendectomy alone for many 1-2 cm tumors rather than automatic completion hemicolectomy.
Mechanism Target:
INHIBITS Appendiceal Enteroendocrine-Cell Neoplasia — Complete appendectomy removes the localized appendiceal tumor.
Show evidence (1 reference)
PMID:38168835 SUPPORT Other
"Simple appendectomy is sufficient in tumors < 1 cm while extended surgery is indicated in tumors > 2 cm."
The contemporary review directly supports appendectomy as definitive local treatment for tumors smaller than 1 cm.
Show evidence (2 references)
PMID:38168835 SUPPORT Other
"Simple appendectomy is sufficient in tumors < 1 cm while extended surgery is indicated in tumors > 2 cm."
The update directly supports appendectomy for sub-centimeter tumors.
PMID:36640790 SUPPORT Human Clinical
"This study provides evidence that right-sided hemicolectomy is not indicated after complete resection of an appendiceal NET of 1-2 cm in size by appendectomy"
The long-follow-up pooled cohort supports appendectomy alone after complete resection in the 1-2 cm group.
Selected Completion Right Hemicolectomy
Category: Therapeutic Action: right colectomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is right colectomy (NCIT:C51623). NCIT:C51623 is a clinical intervention from the NCI Thesaurus. Ontology label: Right Colectomy NCIT:C51623
Extended surgery is indicated for tumors larger than 2 cm and can be considered in selected 1-2 cm cases with incomplete resection or higher grade. It should not be presented as routine after complete appendectomy for every 1-2 cm tumor because pooled long-term data found no survival advantage.
Show evidence (2 references)
PMID:38168835 SUPPORT Other
"In a multicenter study of aNENs measuring 1-2 cm, extended surgery offered no significant prognostic advantage and is now limited to incomplete tumor resection or high-grade G2 or G3 aNEN."
The review restricts extended surgery in the intermediate-size group to selected higher-risk contexts.
PMID:36640790 SUPPORT Human Clinical
"Overall survival was similar between patients with appendectomy and right-sided hemicolectomy"
The pooled cohort directly supports avoiding routine hemicolectomy solely because a completely resected tumor measures 1-2 cm.
Somatostatin Analogues for Rare Advanced or Functional Disease
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: octreotide CHEBI:7726 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses octreotide (CHEBI:7726). CHEBI:7726 is a therapeutic agent from Chemical Entities of Biological Interest.
Somatostatin analogues such as octreotide are systemic options for advanced gastroenteropancreatic NETs and hormone-syndrome control. Their inclusion here is limited to rare advanced or functional appendiceal disease and is an extrapolation from the broader gastrointestinal NET evidence base, not an appendiceal-specific trial result.
Show evidence (1 reference)
PMID:28286921 SUPPORT Other
"Current and emerging treatment options include somatostatin analogs, radiolabeled somatostatin analogs, the mTOR inhibitor everolimus, and the tyrosine kinase inhibitor sunitinib."
The review supports somatostatin analogues for metastatic gastrointestinal NETs generally; application to appendiceal primaries is explicitly extrapolated.
Selective Post-Treatment Surveillance
Category: Monitoring Action: surveillance for malignanciesNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surveillance for malignancies, annotated with Cancer Screening (NCIT:C15406). NCIT:C15406 is a clinical intervention from the NCI Thesaurus. Ontology label: Cancer Screening NCIT:C15406
Follow-up intensity is individualized because recurrence is rare but can be very late, while routine imaging and biomarker schedules remain insufficiently validated. This is a monitoring action, not antitumor therapy.
Show evidence (2 references)
PMID:33004273 SUPPORT Human Clinical
"Recurrence is rare, and in this series only occurred decades later, making a compelling case for selective surveillance and follow-up."
The long-term cohort supports selective rather than universally intensive surveillance.
PMID:38168835 SUPPORT Other
"Follow-up remains debatable, as the use of imaging and biomarkers lacks validation."
The contemporary review directly documents the evidence gap around follow-up tools.
🔬

Diagnosis

3
Appendectomy-Specimen Histopathology and Risk Assessment (Diagnosis is commonly established by histopathologic examination of an appendectomy specimen, followed by documentation of tumor size, depth of invasion, margins, and Ki67 proliferation index.)
diagnostic procedure NCIT:C18020 NCI Thesaurus (NCIT)
Results: A well-differentiated appendiceal neuroendocrine tumor establishes the diagnosis; size, invasion, margins, and Ki67 refine postoperative risk assessment.
Show evidence (1 reference)
PMID:38833137 SUPPORT Human Clinical
"Appendiceal neuroendocrine tumors (NETs) are common and often are identified as incidental lesions at the time of appendectomy. The guidelines for management are based on tumor size, degree of invasion, and the Ki67 proliferation index."
The appendiceal series directly supports incidental pathologic diagnosis and the principal postoperative risk variables.
Tumor-Cell Immunophenotyping (When tumor-cell typing is clinically relevant, immunohistochemistry for serotonin and L-cell-associated hormones and markers can distinguish EC-cell, L-cell, and mixed patterns.)
Immunohistochemistry Staining Method NCIT:C23020 NCI Thesaurus (NCIT)
Results: Serotonin-predominant staining supports EC-cell differentiation; GLP, PYY, or PP staining supports L-cell differentiation; combined expression supports a mixed pattern.
Show evidence (1 reference)
PMID:38833137 SUPPORT Human Clinical
"Immunohistochemistry identified three types of appendiceal NETs."
The cohort directly supports immunohistochemical separation of three tumor-cell patterns.
Selective Hormone-Directed Biochemistry (Urinary 5-HIAA is considered only for a serotonin-producing tumor context; GLPs and/or pancreatic polypeptide are more biologically aligned with an L-cell tumor. These measurements are not universal screening tests for every localized appendiceal NET.)
urine chemistry measurement NCIT:C61044 NCI Thesaurus (NCIT)
Results: Elevated urinary 5-HIAA supports serotonin production but a normal result does not exclude an L-cell or nonfunctioning appendiceal NET.
Show evidence (1 reference)
PMID:38833137 SUPPORT Human Clinical
"monitoring urinary 5HIAA levels is only appropriate for patients with serotonin-producing tumors, whereas measurement of GLPs and/or PP is more appropriate for patients with L-cell tumors."
This disease-specific series directly supports phenotype-directed rather than universal biochemical testing.
📈

Progression

2
Incidental localized disease
Most appendiceal NETs are clinically silent and are discovered by pathologic examination after appendectomy, commonly performed for a clinical presentation attributed to appendicitis. The appendicitis presentation should not be treated as proof that the tumor caused the inflammation in every patient.
Show evidence (1 reference)
PMID:37574653 SUPPORT Other
"Most acute presentations are attributed clinically to appendicitis, with most cases detected incidentally on pathology after an appendectomy."
The review directly supports the common incidental route to diagnosis while preserving the distinction between clinical attribution and established tumor causation.
Rare regional or distant progression
Recurrence and disease-specific death are uncommon, but late recurrence can occur. Long-term follow-up is therefore selective rather than automatically intensive for every completely resected small tumor.
Show evidence (1 reference)
PMID:33004273 SUPPORT Human Clinical
"aNETs are indolent with very high rates of overall and relapse-free survival. Recurrence is rare, and in this series only occurred decades later, making a compelling case for selective surveillance and follow-up."
The long-term cohort supports an uncommon but potentially late progressive phase and a selective surveillance strategy.
🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Appendiceal Neuroendocrine Tumor:

Goblet Cell Adenocarcinoma
Overlapping Features Goblet cell adenocarcinoma, historically called goblet cell carcinoid, is an amphicrine appendiceal epithelial malignancy with glandular and neuroendocrine differentiation. Despite historical terminology and partial neuroendocrine marker expression, it is not an appendiceal NET subtype.
Distinguishing Features
  • Glandular or mucinous morphology with goblet-cell differentiation rather than a conventional well-differentiated NET pattern.
  • Staged and treated as an adenocarcinoma rather than as an appendiceal neuroendocrine tumor.
  • A mutational profile distinct from both appendiceal NET and conventional appendiceal adenocarcinoma in the available genomic series.
Show evidence (2 references)
PMID:29634977 SUPPORT Human Clinical
"Goblet cell carcinoid (GCC) is a rare appendiceal tumor with unique morphologic features that shows glandular and neuroendocrine differentiation on immunohistochemistry. An additional component of adenocarcinoma (AC) can be present (GCC-AC). Both GCC and GCC-AC are staged and treated like AC."
The genomic-pathology series directly establishes the amphicrine morphology and adenocarcinoma management framework.
PMID:29634977 SUPPORT Human Clinical
"This limited series reveals mutations in SOX9, RHOA, and chromatin-modifier genes in goblet cell tumors, and shows that the mutational profile of GCC/GCC-AC is distinct from NET and conventional appendiceal AC."
The molecular distinction supports modeling goblet cell adenocarcinoma as a differential rather than a subtype.
{ }

Source YAML

click to show 
name: Appendiceal Neuroendocrine Tumor
creation_date: "2026-06-08T00:00:00Z"
description: >-
  Appendiceal neuroendocrine tumors (appendiceal NETs) are well-differentiated
  epithelial neuroendocrine neoplasms of the vermiform appendix that are often
  detected incidentally in appendectomy specimens. They are heterogeneous rather
  than uniformly serotonin-producing: a 135-tumor series classified 56% as
  enterochromaffin (EC)-cell tumors, 27% as L-cell tumors, and 17% as mixed tumors.
  Most localized tumors are indolent, but tumor size, invasion, and Ki67-based grade
  inform risk assessment. Appendectomy is sufficient for tumors smaller than 1 cm
  and, after complete resection, for many tumors measuring 1-2 cm; routine completion
  right hemicolectomy has not shown a survival advantage in the 1-2 cm group.
  Serotonin-directed biochemistry and carcinoid-syndrome assumptions apply only to
  the serotonin-producing branch. Goblet cell adenocarcinoma is a distinct
  appendiceal epithelial malignancy, not an appendiceal NET subtype.
categories:
- Solid Tumor
- Gastrointestinal Cancer
- Neuroendocrine Neoplasm
parents:
- neuroendocrine tumor
- appendix cancer
disease_term:
  preferred_term: appendiceal neuroendocrine tumor
  term:
    id: MONDO:0015066
    label: neuroendocrine tumor of the appendix, well differentiated, low or intermediate grade
progression:
- phase: Incidental localized disease
  notes: >-
    Most appendiceal NETs are clinically silent and are discovered by pathologic
    examination after appendectomy, commonly performed for a clinical presentation
    attributed to appendicitis. The appendicitis presentation should not be treated
    as proof that the tumor caused the inflammation in every patient.
  evidence:
  - reference: PMID:37574653
    reference_title: "Appendiceal Neuroendocrine Neoplasms: A Comprehensive Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Most acute presentations are attributed clinically to appendicitis, with most
      cases detected incidentally on pathology after an appendectomy.
    explanation: >-
      The review directly supports the common incidental route to diagnosis while
      preserving the distinction between clinical attribution and established tumor
      causation.
- phase: Rare regional or distant progression
  notes: >-
    Recurrence and disease-specific death are uncommon, but late recurrence can occur.
    Long-term follow-up is therefore selective rather than automatically intensive for
    every completely resected small tumor.
  evidence:
  - reference: PMID:33004273
    reference_title: The impact of lymph node metastases and right hemicolectomy on outcomes in appendiceal neuroendocrine tumours (aNETs).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aNETs are indolent with very high rates of overall and relapse-free survival.
      Recurrence is rare, and in this series only occurred decades later, making a
      compelling case for selective surveillance and follow-up.
    explanation: >-
      The long-term cohort supports an uncommon but potentially late progressive
      phase and a selective surveillance strategy.
pathophysiology:
- name: Appendiceal Enteroendocrine-Cell Neoplasia
  description: >-
    A well-differentiated epithelial neuroendocrine neoplasm develops in the
    appendiceal enteroendocrine-cell compartment. This disease-level initiating node
    does not assume that every tumor has EC-cell differentiation or serotonin
    production.
  biological_scale: TISSUE
  cell_types:
  - preferred_term: enteroendocrine cell
    term:
      id: CL:0000164
      label: enteroendocrine cell
  locations:
  - preferred_term: vermiform appendix
    term:
      id: UBERON:0001154
      label: vermiform appendix
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:38833137
    reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Appendiceal neuroendocrine tumors (NETs) are common and often are identified as
      incidental lesions at the time of appendectomy.
    explanation: >-
      This appendiceal pathology series establishes the organ-specific neuroendocrine
      neoplasm studied by this node.
  downstream:
  - target: EC-, L-, and Mixed-Cell Tumor Differentiation
    description: >-
      Appendiceal NETs differentiate into at least three immunophenotypic cell-type
      patterns.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38833137
      reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Immunohistochemistry identified three types of appendiceal NETs. There were 75
        (56%) classified as EC-cell tumors and 37 (27%) classified as L-cell tumors;
        the remaining 23 (17%) expressed serotonin and one of the L-cell biomarkers
        and were classified as mixed.
      explanation: >-
        The cohort directly defines the EC-cell, L-cell, and mixed differentiation
        patterns.
  - target: Tumor Growth and Tissue Invasion
    description: >-
      Neoplastic outgrowth produces a measurable appendiceal tumor that can extend
      through the appendiceal wall and into the mesoappendix.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33754384
      reference_title: "Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Small (<5 mm) App-NETs that do not invade the serosa or mesoappendix appear to
        be overwhelmingly benign and low-grade
      explanation: >-
        Human pathology links appendiceal tumor size and tissue invasion to behavior,
        but does not resolve every molecular intermediate in tumor progression.
  - target: Appendiceal Neuroendocrine Tumor
    description: >-
      The appendiceal neuroendocrine neoplasm is the defining pathologic phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33754384
      reference_title: "Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Appendiceal well-differentiated neuroendocrine tumours (NETs) are usually
        incidental and clinically benign.
      explanation: >-
        The cohort directly identifies the defining appendiceal well-differentiated
        neuroendocrine-tumor phenotype.
- name: EC-, L-, and Mixed-Cell Tumor Differentiation
  description: >-
    Appendiceal NETs show EC-cell, L-cell, or mixed immunophenotypic differentiation.
    In the available 135-tumor retrospective series, EC-cell tumors were the largest
    group but were not universal; L-cell tumors formed more than one quarter of cases.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: enteroendocrine cell
    term:
      id: CL:0000164
      label: enteroendocrine cell
  biological_processes:
  - preferred_term: cell differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030154
      label: cell differentiation
  evidence:
  - reference: PMID:38833137
    reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our study confirms that appendiceal NETs are not a homogeneous tumor
      population. There are at least three types of appendiceal NET, including
      EC-cell, L-cell, and mixed tumors.
    explanation: >-
      The series directly establishes cell-type heterogeneity within appendiceal
      NETs.
  downstream:
  - target: Serotonin-Producing EC-Cell Branch
    description: >-
      EC-cell differentiation defines the serotonin-producing branch; mixed tumors
      can also express serotonin.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38833137
      reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        There were 75 (56%) classified as EC-cell tumors and 37 (27%) classified as
        L-cell tumors; the remaining 23 (17%) expressed serotonin and one of the
        L-cell biomarkers and were classified as mixed.
      explanation: >-
        The immunophenotypic series directly links EC-cell and a subset of mixed
        tumors to serotonin expression.
  - target: Tumor Growth and Tissue Invasion
    description: >-
      Cell phenotype was associated with size and invasion in one retrospective
      series, with EC-cell tumors showing the greatest and mixed tumors intermediate
      involvement.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:38833137
      reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        EC-cell tumors were significantly larger with more extensive invasion
        involving the muscularis propria, subserosa, and mesoappendix compared with
        L-cell tumors. Mixed tumors were intermediate in all of these parameters.
      explanation: >-
        This supports a human association between cell phenotype and invasive
        behavior, but not a fully resolved causal mechanism.
- name: Serotonin-Producing EC-Cell Branch
  description: >-
    EC-cell tumors, and the serotonin-expressing component of mixed tumors, retain a
    serotonin-producing phenotype. This branch is explicitly conditional and must not
    be generalized to L-cell tumors or to every appendiceal NET.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: type EC enteroendocrine cell
    term:
      id: CL:0000577
      label: type EC enteroendocrine cell
  biological_processes:
  - preferred_term: serotonin biosynthetic process
    modifier: INCREASED
    term:
      id: GO:0042427
      label: serotonin biosynthetic process
  - preferred_term: serotonin secretion
    modifier: INCREASED
    term:
      id: GO:0001820
      label: serotonin secretion
  evidence:
  - reference: PMID:38833137
    reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This information is important for surveillance of patients, as monitoring
      urinary 5HIAA levels is only appropriate for patients with serotonin-producing
      tumors, whereas measurement of GLPs and/or PP is more appropriate for patients
      with L-cell tumors.
    explanation: >-
      The disease-specific series restricts serotonin-metabolite monitoring to the
      serotonin-producing tumor branch and identifies a different biochemical program
      for L-cell tumors.
- name: Tumor Growth and Tissue Invasion
  description: >-
    Increasing tumor size and extension into the serosa or mesoappendix mark a more
    advanced local lesion. Size is associated with nodal disease, but small tumors
    confined to the appendix are overwhelmingly indolent.
  biological_scale: TISSUE
  locations:
  - preferred_term: vermiform appendix
    term:
      id: UBERON:0001154
      label: vermiform appendix
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:33754384
    reference_title: "Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Increasing tumour size was associated with an increased risk of nodal disease
    explanation: >-
      This pathology cohort directly supports tumor size as a clinical risk correlate
      for nodal involvement.
  downstream:
  - target: Regional Nodal and Rare Distant Spread
    description: >-
      Larger and invasive tumors have a higher observed probability of regional nodal
      involvement, although the biological intermediates and prognostic importance of
      nodal disease remain incompletely resolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33754384
      reference_title: "Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Increasing tumour size was associated with an increased risk of nodal disease
      explanation: >-
        The observed size-node association supports the clinical edge while leaving
        the intervening biology and causal direction incompletely specified.
- name: Regional Nodal and Rare Distant Spread
  description: >-
    A minority of appendiceal NETs involve regional lymph nodes, whereas distant
    metastasis and tumor-related mortality are rare in contemporary long-term cohorts.
    The clinical importance of microscopic regional nodal disease is disputed.
  biological_scale: TISSUE
  evidence:
  - reference: PMID:36640790
    reference_title: "Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Regional lymph node metastases were found in 22 (20%) of 112 patients with
      right-sided hemicolectomy with available data.
    explanation: >-
      The pooled cohort documents regional nodal involvement in resected 1-2 cm
      tumors.
  - reference: PMID:36640790
    reference_title: "Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All metastases were diagnosed synchronously with no tumour-related deaths during
      follow-up.
    explanation: >-
      The same long-follow-up cohort supports the rarity and limited mortality impact
      of distant spread in this size-defined population.
histopathology:
- name: Well-Differentiated Appendiceal Neuroendocrine Tumor
  diagnostic: true
  description: >-
    The defining microscopic lesion is a well-differentiated epithelial
    neuroendocrine tumor in the appendix. Tumor size, depth of invasion, and Ki67
    proliferation index are recorded for risk stratification; G1 and G2 are grades,
    not separate disease subtypes in this entry.
  evidence:
  - reference: PMID:38833137
    reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The guidelines for management are based on tumor size, degree of invasion, and
      the Ki67 proliferation index.
    explanation: >-
      The appendiceal pathology series directly supports the core histopathologic risk
      variables.
- name: EC-, L-, and Mixed-Cell Immunophenotypes
  description: >-
    Immunohistochemistry for serotonin and L-cell-associated markers can resolve
    EC-cell, L-cell, and mixed appendiceal NET patterns. This is a tumor-cell
    classification within appendiceal NET, not a claim that each pattern is yet a
    validated independent clinical subtype.
  evidence:
  - reference: PMID:38833137
    reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We analyzed the expression of biomarkers including CDX2, SATB2, PSAP,
      serotonin, glucagon (that detects GLPs), PYY, and pancreatic polypeptide (PP)
      and correlated the results with clinicopathologic parameters.
    explanation: >-
      The series directly describes the immunohistochemical marker panel used for
      tumor-cell classification.
phenotypes:
- name: Appendiceal Neuroendocrine Tumor
  category: Neoplastic
  frequency: OBLIGATE
  diagnostic: true
  description: >-
    A well-differentiated neuroendocrine tumor of the appendix is the defining lesion.
    Carcinoid syndrome manifestations are not listed as general disease phenotypes
    because they apply only to rare advanced serotonin-producing disease and were not
    supported by appendiceal-specific cohort evidence in this review.
  phenotype_term:
    preferred_term: Carcinoid tumor
    term:
      id: HP:0100570
      label: Carcinoid tumor
  evidence:
  - reference: PMID:33754384
    reference_title: "Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Appendiceal well-differentiated neuroendocrine tumours (NETs) are usually
      incidental and clinically benign.
    explanation: >-
      This cohort directly supports the defining tumor phenotype and its usually
      incidental, indolent presentation.
diagnosis:
- name: Appendectomy-Specimen Histopathology and Risk Assessment
  presence: >-
    Diagnosis is commonly established by histopathologic examination of an
    appendectomy specimen, followed by documentation of tumor size, depth of invasion,
    margins, and Ki67 proliferation index.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  results: >-
    A well-differentiated appendiceal neuroendocrine tumor establishes the diagnosis;
    size, invasion, margins, and Ki67 refine postoperative risk assessment.
  evidence:
  - reference: PMID:38833137
    reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Appendiceal neuroendocrine tumors (NETs) are common and often are identified as
      incidental lesions at the time of appendectomy. The guidelines for management
      are based on tumor size, degree of invasion, and the Ki67 proliferation index.
    explanation: >-
      The appendiceal series directly supports incidental pathologic diagnosis and the
      principal postoperative risk variables.
- name: Tumor-Cell Immunophenotyping
  presence: >-
    When tumor-cell typing is clinically relevant, immunohistochemistry for serotonin
    and L-cell-associated hormones and markers can distinguish EC-cell, L-cell, and
    mixed patterns.
  diagnosis_term:
    preferred_term: Immunohistochemistry Staining Method
    term:
      id: NCIT:C23020
      label: Immunohistochemistry Staining Method
  results: >-
    Serotonin-predominant staining supports EC-cell differentiation; GLP, PYY, or PP
    staining supports L-cell differentiation; combined expression supports a mixed
    pattern.
  evidence:
  - reference: PMID:38833137
    reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immunohistochemistry identified three types of appendiceal NETs.
    explanation: >-
      The cohort directly supports immunohistochemical separation of three tumor-cell
      patterns.
- name: Selective Hormone-Directed Biochemistry
  presence: >-
    Urinary 5-HIAA is considered only for a serotonin-producing tumor context; GLPs
    and/or pancreatic polypeptide are more biologically aligned with an L-cell tumor.
    These measurements are not universal screening tests for every localized
    appendiceal NET.
  diagnosis_term:
    preferred_term: urine chemistry measurement
    term:
      id: NCIT:C61044
      label: Urine Chemistry Measurement
  results: >-
    Elevated urinary 5-HIAA supports serotonin production but a normal result does not
    exclude an L-cell or nonfunctioning appendiceal NET.
  evidence:
  - reference: PMID:38833137
    reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      monitoring urinary 5HIAA levels is only appropriate for patients with
      serotonin-producing tumors, whereas measurement of GLPs and/or PP is more
      appropriate for patients with L-cell tumors.
    explanation: >-
      This disease-specific series directly supports phenotype-directed rather than
      universal biochemical testing.
differential_diagnoses:
- name: Goblet Cell Adenocarcinoma
  description: >-
    Goblet cell adenocarcinoma, historically called goblet cell carcinoid, is an
    amphicrine appendiceal epithelial malignancy with glandular and neuroendocrine
    differentiation. Despite historical terminology and partial neuroendocrine marker
    expression, it is not an appendiceal NET subtype.
  distinguishing_features:
  - Glandular or mucinous morphology with goblet-cell differentiation rather than a conventional well-differentiated NET pattern.
  - Staged and treated as an adenocarcinoma rather than as an appendiceal neuroendocrine tumor.
  - A mutational profile distinct from both appendiceal NET and conventional appendiceal adenocarcinoma in the available genomic series.
  evidence:
  - reference: PMID:29634977
    reference_title: Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Goblet cell carcinoid (GCC) is a rare appendiceal tumor with unique morphologic
      features that shows glandular and neuroendocrine differentiation on
      immunohistochemistry. An additional component of adenocarcinoma (AC) can be
      present (GCC-AC). Both GCC and GCC-AC are staged and treated like AC.
    explanation: >-
      The genomic-pathology series directly establishes the amphicrine morphology and
      adenocarcinoma management framework.
  - reference: PMID:29634977
    reference_title: Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This limited series reveals mutations in SOX9, RHOA, and chromatin-modifier
      genes in goblet cell tumors, and shows that the mutational profile of GCC/GCC-AC
      is distinct from NET and conventional appendiceal AC.
    explanation: >-
      The molecular distinction supports modeling goblet cell adenocarcinoma as a
      differential rather than a subtype.
treatments:
- name: Appendectomy
  description: >-
    Simple appendectomy is sufficient for tumors smaller than 1 cm. After complete
    primary-tumor resection, long-term pooled data also support appendectomy alone for
    many 1-2 cm tumors rather than automatic completion hemicolectomy.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: appendectomy
    term:
      id: NCIT:C51687
      label: Appendectomy
  therapeutic_modality: SURGERY
  target_mechanisms:
  - target: Appendiceal Enteroendocrine-Cell Neoplasia
    treatment_effect: INHIBITS
    description: Complete appendectomy removes the localized appendiceal tumor.
    evidence:
    - reference: PMID:38168835
      reference_title: "Appendiceal Neuroendocrine Neoplasms: an Update for 2023."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Simple appendectomy is sufficient in tumors < 1 cm while extended surgery is
        indicated in tumors > 2 cm.
      explanation: >-
        The contemporary review directly supports appendectomy as definitive local
        treatment for tumors smaller than 1 cm.
  evidence:
  - reference: PMID:38168835
    reference_title: "Appendiceal Neuroendocrine Neoplasms: an Update for 2023."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Simple appendectomy is sufficient in tumors < 1 cm while extended surgery is
      indicated in tumors > 2 cm.
    explanation: >-
      The update directly supports appendectomy for sub-centimeter tumors.
  - reference: PMID:36640790
    reference_title: "Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study provides evidence that right-sided hemicolectomy is not indicated
      after complete resection of an appendiceal NET of 1-2 cm in size by appendectomy
    explanation: >-
      The long-follow-up pooled cohort supports appendectomy alone after complete
      resection in the 1-2 cm group.
- name: Selected Completion Right Hemicolectomy
  description: >-
    Extended surgery is indicated for tumors larger than 2 cm and can be considered in
    selected 1-2 cm cases with incomplete resection or higher grade. It should not be
    presented as routine after complete appendectomy for every 1-2 cm tumor because
    pooled long-term data found no survival advantage.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: right colectomy
    term:
      id: NCIT:C51623
      label: Right Colectomy
  therapeutic_modality: SURGERY
  evidence:
  - reference: PMID:38168835
    reference_title: "Appendiceal Neuroendocrine Neoplasms: an Update for 2023."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In a multicenter study of aNENs measuring 1-2 cm, extended surgery offered no
      significant prognostic advantage and is now limited to incomplete tumor
      resection or high-grade G2 or G3 aNEN.
    explanation: >-
      The review restricts extended surgery in the intermediate-size group to selected
      higher-risk contexts.
  - reference: PMID:36640790
    reference_title: "Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Overall survival was similar between patients with appendectomy and right-sided
      hemicolectomy
    explanation: >-
      The pooled cohort directly supports avoiding routine hemicolectomy solely because
      a completely resected tumor measures 1-2 cm.
- name: Somatostatin Analogues for Rare Advanced or Functional Disease
  description: >-
    Somatostatin analogues such as octreotide are systemic options for advanced
    gastroenteropancreatic NETs and hormone-syndrome control. Their inclusion here is
    limited to rare advanced or functional appendiceal disease and is an extrapolation
    from the broader gastrointestinal NET evidence base, not an appendiceal-specific
    trial result.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: octreotide
      term:
        id: CHEBI:7726
        label: octreotide
  therapeutic_modality: PEPTIDE
  evidence:
  - reference: PMID:28286921
    reference_title: Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Current and emerging treatment options include somatostatin analogs,
      radiolabeled somatostatin analogs, the mTOR inhibitor everolimus, and the
      tyrosine kinase inhibitor sunitinib.
    explanation: >-
      The review supports somatostatin analogues for metastatic gastrointestinal NETs
      generally; application to appendiceal primaries is explicitly extrapolated.
- name: Selective Post-Treatment Surveillance
  description: >-
    Follow-up intensity is individualized because recurrence is rare but can be very
    late, while routine imaging and biomarker schedules remain insufficiently
    validated. This is a monitoring action, not antitumor therapy.
  action_category: MONITORING
  treatment_term:
    preferred_term: surveillance for malignancies
    term:
      id: NCIT:C15406
      label: Cancer Screening
  evidence:
  - reference: PMID:33004273
    reference_title: The impact of lymph node metastases and right hemicolectomy on outcomes in appendiceal neuroendocrine tumours (aNETs).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recurrence is rare, and in this series only occurred decades later, making a
      compelling case for selective surveillance and follow-up.
    explanation: >-
      The long-term cohort supports selective rather than universally intensive
      surveillance.
  - reference: PMID:38168835
    reference_title: "Appendiceal Neuroendocrine Neoplasms: an Update for 2023."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Follow-up remains debatable, as the use of imaging and biomarkers lacks
      validation.
    explanation: >-
      The contemporary review directly documents the evidence gap around follow-up
      tools.
discussions:
- discussion_id: gap_appendiceal_net_cell_type_prognosis
  prompt: >-
    Does EC-cell, L-cell, or mixed-cell differentiation independently predict
    clinically meaningful recurrence or survival after adjustment for tumor size,
    grade, and invasion?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#EC-, L-, and Mixed-Cell Tumor Differentiation
  - pathophysiology#Tumor Growth and Tissue Invasion
  rationale: >-
    One retrospective 135-tumor series found strong clinicopathologic differences by
    cell phenotype, but broader validation is needed before cell typing can be treated
    as an independent management classifier.
  evidence:
  - reference: PMID:38833137
    reference_title: "The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tumor type correlated with pT stage and the only patient with distant metastatic
      disease in this series had an EC-cell tumor.
    explanation: >-
      The single retrospective series motivates, but does not resolve, independent
      prognostic validation of cell type.
- discussion_id: controversy_appendiceal_net_surgery_and_follow_up
  prompt: >-
    Which patients with completely resected 1-2 cm appendiceal NETs benefit from
    completion right hemicolectomy or structured long-term surveillance?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - treatments#Appendectomy
  - treatments#Selected Completion Right Hemicolectomy
  - treatments#Selective Post-Treatment Surveillance
  rationale: >-
    Long-follow-up cohorts find no survival advantage from routine hemicolectomy in
    completely resected 1-2 cm tumors, yet the optimal interpretation of nodal disease
    and the design and duration of follow-up remain unsettled.
  evidence:
  - reference: PMID:38168835
    reference_title: "Appendiceal Neuroendocrine Neoplasms: an Update for 2023."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Future studies should address the prognostic impact of lymph node metastases and
      the optimal design and duration of follow-up.
    explanation: >-
      The review directly identifies the unresolved nodal-prognosis and follow-up
      questions.
  - reference: PMID:36640790
    reference_title: "Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Overall survival was similar between patients with appendectomy and right-sided
      hemicolectomy
    explanation: >-
      The pooled cohort supplies the central comparative evidence behind surgical
      de-escalation in this group.
datasets: []
review_notes: >-
  The 2026 re-review removed WHO grades and goblet cell adenocarcinoma from the subtype
  list, replaced a universal EC-cell/serotonin/carcinoid-syndrome model with
  appendiceal-specific EC-, L-, and mixed-cell evidence, removed unsupported general
  symptoms, added pathology and differential-diagnosis structure, and calibrated
  surgery and surveillance to long-term comparative cohorts. The somatostatin-analogue
  statement is retained only as explicitly labeled extrapolation for rare advanced
  gastrointestinal NET disease.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Appendiceal Neuroendocrine Tumor (aNET/ANET) — Disease Characteristics Research Report
Edison Scientific Literature 32 citations 2026-06-08T18:30:49.259656

Appendiceal Neuroendocrine Tumor (aNET/ANET) — Disease Characteristics Research Report

Target Disease

  • Disease Name: Appendiceal Neuroendocrine Tumor (appendiceal neuroendocrine neoplasm)
  • MONDO ID: Not identified from the retrieved sources in this run (see “Key identifiers” below).
  • Category: Gastrointestinal neuroendocrine neoplasm (appendix primary).

Executive summary (current understanding)

Appendiceal neuroendocrine neoplasms (ANENs) are uncommon tumors of the appendix, most often sporadic, non-functioning, well-differentiated NETs (G1–G2) that are incidentally discovered in appendectomy specimens obtained for suspected appendicitis. Management is primarily surgical, with appendectomy adequate for most tumors <1 cm and right hemicolectomy (RHC) generally recommended for tumors ≥2 cm; however, the benefit of completion RHC for 1–2 cm tumors has been challenged by a large Europe-wide pooled cohort study showing no survival advantage and no metachronous metastases after complete resection. (andrini2023anupdateon pages 1-3, mohamed2022managementofappendix pages 1-2, nesti2023hemicolectomyversusappendectomy pages 5-12)

Topic Key finding (with numbers) Source (author/year/journal) URL/DOI Evidence type
Definition / classification Appendiceal neuroendocrine neoplasms include well-differentiated NETs (formerly “carcinoid tumors”), poorly differentiated NECs, and MiNENs; ~70–75% are well-differentiated NETs graded G1–G3 by Ki-67 and/or mitotic index. (mohamed2022managementofappendix pages 1-2, mohamed2022managementofappendix pages 2-4) Mohamed et al., 2022, Cancers https://doi.org/10.3390/cancers15010295 Review/guideline synthesis
Epidemiology / incidence aNET annual incidence reported at ~0.15–0.6 per 100,000; peak age 38–51 years; female predominance ~2:1; found in ~3–5 per 1,000 appendectomies; most arise at the appendix tip (~70%). (andrini2023anupdateon pages 1-3) Andrini et al., 2023, Current Treatment Options in Oncology https://doi.org/10.1007/s11864-023-01093-0 Review
Epidemiology / incidence trends In SEER 2000–2017, appendiceal NET incidence increased from 0.03 to 0.90 per 100,000 person-years, with the largest increase in localized disease; survival also improved over time. (wang2023incidencetrendsand pages 13-14) Wang et al., 2023, PLOS ONE https://doi.org/10.1371/journal.pone.0294153 Population-based registry study
Stage at diagnosis SEER (1973–2004) distribution: 60% localized, 28% regional, 12% distant at presentation. (mohamed2022managementofappendix pages 1-2) Mohamed et al., 2022, Cancers https://doi.org/10.3390/cancers15010295 Review of registry data
Nodal metastasis by size Reported nodal metastasis rates rise with size: ~2.5% for <1 cm, 31% for 1–2 cm, and 64% for ≥2 cm. (andrini2023anupdateon pages 1-3) Andrini et al., 2023, Current Treatment Options in Oncology https://doi.org/10.1007/s11864-023-01093-0 Review
Nodal metastasis by size (alternative dataset) SEER analyses summarized rates of 15% (<1 cm), 47% (1.0–1.9 cm), and 86% (>2 cm); another series reported 31% for 1.1–2 cm and 64% for >2 cm. (mohamed2022managementofappendix pages 4-5) Mohamed et al., 2022, Cancers https://doi.org/10.3390/cancers15010295 Review of registry studies
Distant metastasis / carcinoid syndrome Carcinoid syndrome is very rare (<1%) and generally occurs only with metastases. (andrini2023anupdateon pages 1-3) Andrini et al., 2023, Current Treatment Options in Oncology https://doi.org/10.1007/s11864-023-01093-0 Review
Surgery threshold: appendectomy Consensus summarized by guidelines supports appendectomy for tumors <1 cm, and for 1.0–1.9 cm tumors without high-risk features. (mohamed2022managementofappendix pages 4-5) Mohamed et al., 2022, Cancers https://doi.org/10.3390/cancers15010295 Review/guideline synthesis
Surgery threshold: right hemicolectomy Most guidelines recommend right hemicolectomy for tumors >2 cm; high-risk features include deep mesoappendiceal invasion >3 mm, positive/unclear margins, lymphovascular invasion, and higher proliferative rate. (mohamed2022managementofappendix pages 4-5) Mohamed et al., 2022, Cancers https://doi.org/10.3390/cancers15010295 Review/guideline synthesis
Intermediate tumors (1–2 cm) Authors suggest considering right hemicolectomy when tumor size is >15 mm and/or G2 and/or lymphovascular invasion, ideally after multidisciplinary review. (andrini2023anupdateon pages 1-3, andrini2023anupdateon pages 7-9) Andrini et al., 2023, Current Treatment Options in Oncology https://doi.org/10.1007/s11864-023-01093-0 Expert review/opinion
Hemicolectomy vs appendectomy outcomes (1–2 cm) Europe-wide pooled cohort of 278 patients: 163 appendectomy vs 115 hemicolectomy; median follow-up 13.0 years; regional nodal metastases in 22/115 (19.6%); estimated occult nodal disease after appendectomy 12.8% (95% CI 6.5–21.1%); no new metastases during >10 years follow-up; adjusted OS HR 0.88 (95% CI 0.36–2.17; p=0.71), supporting no routine hemicolectomy after complete appendectomy for 1–2 cm aNETs. (nesti2023hemicolectomyversusappendectomy pages 16-21, nesti2023hemicolectomyversusappendectomy pages 5-12, nesti2023hemicolectomyversusappendectomy pages 30-36) Nesti et al., 2023, The Lancet Oncology https://doi.org/10.1016/S1470-2045(22)00750-1 Multicenter pooled retrospective cohort
Recent metastasis study In an institutional series of 124 appendiceal NETs, only 10 had stage IV disease; 8/10 were synchronous, and among 114 early-stage patients none developed distant metastases during follow-up; authors concluded surveillance after resection is unlikely to help and tumors <2 cm should not receive completion hemicolectomy. (altoubah2025doappendicealneuroendocrine pages 1-2, altoubah2025doappendicealneuroendocrine pages 2-3, altoubah2025doappendicealneuroendocrine pages 3-4) Al-Toubah et al., 2025, JNCCN https://doi.org/10.6004/jnccn.2024.7069 Institutional retrospective cohort
Recent completion-surgery study Single-center cohort of 82 patients: lymph-node metastases in 7/82 (8.5%), distant metastases in 3/82 (3.6%); 27/82 (33%) underwent completion hemicolectomy, but only 6/27 (22%) had nodal metastases and none had distant metastases, implying overtreatment in 21/27 (75%); tumor size >2 cm was the only significant predictor of nodal metastasis. (wachter2025retrospectiveanalysisof pages 1-2, wachter2025retrospectiveanalysisof pages 2-4) Wächter et al., 2025, Langenbeck's Archives of Surgery https://doi.org/10.1007/s00423-024-03603-6 Single-center retrospective cohort
Imaging recommendations For NETs >2 cm, incomplete resection, or positive nodes/margins, recommend contrast-enhanced triple-phase CT or MRI; somatostatin-receptor PET with Ga-68 or Cu-64 DOTATATE is preferred and considered the diagnostic/surveillance gold standard for SSTR-positive disease. (mohamed2022managementofappendix pages 4-5) Mohamed et al., 2022, Cancers https://doi.org/10.3390/cancers15010295 Review/guideline synthesis
Imaging in high-grade disease Poorly differentiated/high-grade NECs are better evaluated with 18F-FDG PET plus CT/MRI rather than SSTR-based imaging. (mohamed2022managementofappendix pages 4-5) Mohamed et al., 2022, Cancers https://doi.org/10.3390/cancers15010295 Review/guideline synthesis
Biomarkers Chromogranin A may be elevated but is nonspecific; 5-HIAA (plasma or 24-h urine) is mainly useful in serotonin-producing tumors with carcinoid features or liver metastases. (mohamed2022managementofappendix pages 2-4, mohamed2022managementofappendix pages 4-5) Mohamed et al., 2022, Cancers https://doi.org/10.3390/cancers15010295 Review/guideline synthesis
Survival / prognosis Localized well-differentiated NETs have median OS >20 years; NCDB 5-year survival for ANETs was 86.3% (95% CI 81.4–89.9); 5-year survival by size was 89.9% (≤2 cm), 70.6% (2–4 cm), and 58.2% (>4 cm). (mohamed2022managementofappendix pages 2-4) Mohamed et al., 2022, Cancers https://doi.org/10.3390/cancers15010295 Review of registry data
Follow-up / surveillance Most well-differentiated appendiceal NETs <2 cm with negative margins and mesoappendiceal invasion <3 mm have low recurrence risk and often need no surveillance; postoperative surveillance is unlikely to benefit resected small tumors in recent retrospective data. (mohamed2022managementofappendix pages 4-5, altoubah2025doappendicealneuroendocrine pages 1-2, altoubah2025doappendicealneuroendocrine pages 3-4) Mohamed et al., 2022, Cancers; Al-Toubah et al., 2025, JNCCN https://doi.org/10.3390/cancers15010295; https://doi.org/10.6004/jnccn.2024.7069 Review/guideline synthesis; retrospective cohort

Table: This table compiles key evidence-backed facts about appendiceal neuroendocrine tumors/neoplasms from the retrieved literature, emphasizing incidence, metastatic risk by tumor size, management thresholds, diagnostics, and recent outcome studies. It is designed as a compact reference for evidence-supported knowledge base population.

1. Disease information

What is the disease?

  • Definition / scope: Appendiceal neuroendocrine neoplasms include well-differentiated neuroendocrine tumors (NETs; historically called “carcinoid tumors”), poorly differentiated neuroendocrine carcinomas (NECs), and mixed neuroendocrine–non-neuroendocrine neoplasms (MiNENs) arising in the appendix. (mohamed2022managementofappendix pages 1-2, mohamed2022managementofappendix pages 2-4)
  • Most appendiceal NENs are well-differentiated NETs; a 2022 guideline-synthesis review states ~70–75% are well-differentiated NETs. (mohamed2022managementofappendix pages 1-2)

Key identifiers (OMIM, Orphanet, ICD-10/ICD-11, MeSH, MONDO)

  • Not recovered from the retrieved documents in this run (no ICD/MeSH/MONDO/Orphanet codes were present in accessible excerpts). (mohamed2022managementofappendix pages 1-2)

Synonyms / alternative names

  • Appendiceal neuroendocrine tumor (aNET/ANET)
  • Appendiceal neuroendocrine neoplasm (ANEN)
  • Appendiceal carcinoid tumor (legacy term for well-differentiated appendiceal NET) (mohamed2022managementofappendix pages 1-2)

Evidence provenance

  • The synthesized disease understanding here is derived primarily from aggregated disease-level resources (reviews, guideline syntheses, registry-based cohort studies) plus large pooled/retrospective clinical cohorts. (mohamed2022managementofappendix pages 4-5, nesti2023hemicolectomyversusappendectomy pages 5-12, wachter2025retrospectiveanalysisof pages 1-2)

2. Etiology

Disease causal factors

  • ANENs are described as “usually sporadic tumors” in a guideline-synthesis review. (mohamed2022managementofappendix pages 1-2)

Risk factors

  • Evidence gap in retrieved sources: The retrieved texts emphasize sporadic presentation and incidental detection but do not provide well-supported, tumor-specific environmental or inherited risk factors for appendiceal NET. (mohamed2022managementofappendix pages 1-2)

Protective factors / gene–environment interactions

  • Not identified in the retrieved evidence set. (mohamed2022managementofappendix pages 1-2)

3. Phenotypes (clinical presentation) + suggested HPO terms

Typical presentation

  • Incidental diagnosis after appendectomy for suspected appendicitis is the dominant presentation pattern. (mohamed2022managementofappendix pages 1-2)
  • Tumors are most often located at the distal tip of the appendix. (mohamed2022managementofappendix pages 1-2)
  • Functional syndromes are rare: a 2023 review reports carcinoid syndrome is very rare (<1%), generally occurring only with metastases. (andrini2023anupdateon pages 1-3)

Phenotype characteristics (age of onset, severity, progression)

  • Demographics from a 2023 review: peak age reported as ~38–51 years with female predominance (~2:1). (andrini2023anupdateon pages 1-3)
  • Clinical course is typically indolent for localized well-differentiated tumors, consistent with high long-term survival in registry/retrospective datasets. (mohamed2022managementofappendix pages 2-4, nesti2023hemicolectomyversusappendectomy pages 5-12)

HPO term suggestions (non-exhaustive)

  • Abdominal pain (HPO: Abdominal pain)
  • Acute appendicitis-like presentation (HPO: Appendicitis or Abdominal pain with acute onset)
  • Incidental finding (HPO: Incidental finding)
  • If functional/metastatic:
  • Carcinoid syndrome (HPO: Carcinoid syndrome)
  • Diarrhea (HPO: Diarrhea)
  • Flushing (HPO: Flushing)

Biomarker phenotype links (laboratory abnormalities)

  • Chromogranin A may be elevated but is nonspecific (confounded by renal/hepatic disease and medications). (mohamed2022managementofappendix pages 2-4)
  • 5-HIAA (plasma or 24-hour urine) is mainly useful when serotonin excess is suspected (carcinoid features or liver metastases). (mohamed2022managementofappendix pages 4-5, mohamed2022managementofappendix pages 2-4)

4. Genetic / molecular information

Causal genes / germline predisposition

  • Not identified for appendiceal NET specifically in the retrieved sources. The main high-confidence statements available were that ANENs are typically sporadic. (mohamed2022managementofappendix pages 1-2)

Pathophysiology-linked molecular features (clinically used)

  • Proliferation index (Ki-67) and mitotic rate are central to grading well-differentiated NETs and correlate with behavior. (mohamed2022managementofappendix pages 1-2, mohamed2022managementofappendix pages 2-4)
  • Somatostatin receptor (SSTR) biology is clinically actionable: SSTR-targeted PET is described as preferred and a “gold standard” approach for SSTR-positive disease evaluation/surveillance in guideline syntheses. (mohamed2022managementofappendix pages 4-5)

Proposed ontology annotations

  • Cell types (Cell Ontology; CL) — suggestions:
  • Enteroendocrine cell (CL: enteroendocrine cell; as the relevant neuroendocrine lineage of the gut)
  • GO biological process — suggestions (non-exhaustive):
  • Regulation of cell proliferation
  • Neuroendocrine differentiation
  • Hormone secretion / regulated exocytosis

5. Environmental information

No appendiceal-NET-specific toxin, lifestyle, or infectious triggers were supported in the retrieved evidence set. (mohamed2022managementofappendix pages 1-2)

6. Mechanism / pathophysiology

Mechanistic chain (clinically grounded)

  1. Neuroendocrine neoplastic transformation in appendiceal neuroendocrine lineage cells results in a well-differentiated NET in most cases. (mohamed2022managementofappendix pages 1-2)
  2. Growth and invasion are typically limited in small tumors; however, increasing tumor size and adverse histopathologic features associate with higher probability of regional lymph node metastasis and (rarely) distant spread. (mohamed2022managementofappendix pages 4-5, wachter2025retrospectiveanalysisof pages 1-2)
  3. Systemic functional symptoms (carcinoid syndrome) are uncommon and generally reflect metastatic disease. (andrini2023anupdateon pages 1-3)

Key pathways and cellular processes

  • The retrieved sources did not provide appendiceal-NET-specific pathway alterations (e.g., MAPK/PI3K driver mutations) with primary molecular evidence; thus, pathway-level claims are not made here. (mohamed2022managementofappendix pages 1-2)

7. Anatomical structures affected

Primary organ

  • Appendix (UBERON suggestion: vermiform appendix).

Localization

  • Most tumors arise at the appendiceal tip/distal appendix. (andrini2023anupdateon pages 1-3, mohamed2022managementofappendix pages 1-2)

Metastatic spread (when present)

  • In a large institutional cohort (2008–2023), stage IV disease was rare and, among metastatic cases, common sites included peritoneum and liver, with ovarian involvement noted among females in metastatic subset. (altoubah2025doappendicealneuroendocrine pages 2-3)

8. Temporal development

Onset and course

  • Often detected in young to middle-aged adults and diagnosed after acute presentation leading to appendectomy. (andrini2023anupdateon pages 1-3, mohamed2022managementofappendix pages 1-2)

Progression

  • For completely resected 1–2 cm tumors, a Europe-wide pooled cohort with median 13 years follow-up reported no metachronous distant metastases and no tumor-related deaths. (nesti2023hemicolectomyversusappendectomy pages 5-12)

9. Inheritance and population

Epidemiology (recent data prioritized)

  • Incidence trend (SEER 2000–2017): appendiceal NET incidence increased from 0.03 to 0.90 per 100,000 person-years, with the most pronounced increase in localized disease. (Wang et al., PLOS ONE, published Nov 2023; https://doi.org/10.1371/journal.pone.0294153) (wang2023incidencetrendsand pages 13-14)
  • Reported incidence range: a 2023 review reports annual incidence ~0.15–0.6 per 100,000 and that aNETs are found in approximately 3–5 per 1,000 appendectomies. (Andrini et al., Current Treatment Options in Oncology, May 2023; https://doi.org/10.1007/s11864-023-01093-0) (andrini2023anupdateon pages 1-3)
  • Stage distribution (historical SEER 1973–2004): 60% localized, 28% regional, 12% distant at diagnosis. (mohamed2022managementofappendix pages 1-2)

Inheritance

  • No Mendelian inheritance pattern or specific causal genes were supported by the retrieved appendiceal-NET-focused evidence; tumors are generally described as sporadic. (mohamed2022managementofappendix pages 1-2)

10. Diagnostics

Histopathology / immunohistochemistry

  • Diagnostic confirmation typically relies on postoperative pathology with neuroendocrine immunophenotype markers (e.g., synaptophysin, chromogranin A variably, CD56) and Ki-67 assessment for grading. (vasile2025neuroendocrinetumorsof pages 3-4, kim2025appendicealneuroendocrinetumor pages 4-6)

Imaging

Guideline-synthesis evidence indicates imaging choice depends on risk features and differentiation: - For higher-risk localized disease (e.g., >2 cm, incomplete resection, positive nodes/margins), guidelines recommend contrast-enhanced triple-phase CT or MRI. (mohamed2022managementofappendix pages 4-5) - Somatostatin receptor PET (Ga-68 or Cu-64 DOTATATE) is described as preferred, “gold standard” for SSTR-positive lesions; lesions considered SSTR-positive if uptake exceeds liver background in the cited synthesis. (mohamed2022managementofappendix pages 4-5) - For high-grade NEC, FDG-PET is favored. (mohamed2022managementofappendix pages 4-5) - Reported imaging performance in the 2022 synthesis: FDG-PET/CT sensitivity/specificity 61.9%/100%, and 68Ga-DOTATATE PET/CT sensitivity/specificity approximately 100–81% and 90–80% across studies summarized there (with reported false positives 0–38%). (mohamed2022managementofappendix pages 4-5)

Differential diagnosis

  • The retrieved evidence set did not provide a structured differential diagnosis list; however, the classification framework distinguishes well-differentiated NET from poorly differentiated NEC and MiNEN, which has major prognostic and therapeutic implications. (mohamed2022managementofappendix pages 1-2, mohamed2022managementofappendix pages 2-4)

Visual evidence (staging/management)

  • TNM staging with survival estimates and guideline comparisons for appendectomy vs RHC indications are shown in extracted figures/tables from Mohamed et al. 2022. (mohamed2022managementofappendix media 6bf50e49, mohamed2022managementofappendix media 58ffb4ea, mohamed2022managementofappendix media 5c304756)

11. Outcome / prognosis

Survival and prognostic factors

  • Prognosis is strongly related to tumor size, differentiation/grade, margins, and metastatic stage. (mohamed2022managementofappendix pages 2-4)
  • A guideline-synthesis review summarizing NCDB data reports:
  • 5-year survival for ANETs ~86.3% (95% CI 81.4–89.9). (mohamed2022managementofappendix pages 2-4)
  • Size-stratified 5-year survival: 89.9% (≤2 cm), 70.6% (2–4 cm), 58.2% (>4 cm). (mohamed2022managementofappendix pages 2-4)
  • Stage IV disease appears extremely uncommon in specialty-center populations: an institutional series identified 10 stage IV cases among 124 appendiceal NET patients, and most were synchronous at diagnosis. (altoubah2025doappendicealneuroendocrine pages 1-2)

Nodal metastases and clinical relevance

  • Lymph-node metastasis probability increases with tumor size in registry-based summaries and cohorts. (mohamed2022managementofappendix pages 4-5, wachter2025retrospectiveanalysisof pages 1-2)
  • Importantly, long-term outcomes suggest nodal disease in 1–2 cm tumors may be clinically less consequential: in the Europe-wide pooled cohort, there were no metachronous metastases and no tumor-related deaths after complete resection despite ~20% nodal positivity in the hemicolectomy group. (nesti2023hemicolectomyversusappendectomy pages 5-12)

12. Treatment

Surgical management (real-world implementation + recent developments)

Surgery is the mainstay: - <1 cm: appendectomy is generally considered curative when margins are negative. (mohamed2022managementofappendix pages 4-5, andrini2023anupdateon pages 1-3) - ≥2 cm: most guidelines recommend right hemicolectomy with lymphadenectomy due to higher nodal metastasis risk. (mohamed2022managementofappendix pages 4-5, andrini2023anupdateon pages 1-3) - 1–2 cm: management is controversial; recent high-quality evidence supports de-escalation: - Nesti et al., The Lancet Oncology (Feb 2023, DOI: https://doi.org/10.1016/S1470-2045(22)00750-1) pooled 278 patients (1–2 cm aNET): appendectomy vs hemicolectomy showed no OS benefit (adjusted HR 0.88; p=0.71), and “All metastases were diagnosed synchronously with no tumour-related deaths during the follow-up” (quote from study summary evidence). (nesti2023hemicolectomyversusappendectomy pages 5-12) - A single-center ENETS center retrospective analysis (2025) reported that guideline-based completion RHC may lead to substantial overtreatment: 27/82 (33%) had completion surgery but only 6/27 (22%) had nodal metastases and 0 had distant metastases in completion specimens; tumor size >2 cm was the only significant predictor of nodal metastasis. (Wächter et al., Jan 2025; https://doi.org/10.1007/s00423-024-03603-6) (wachter2025retrospectiveanalysisof pages 1-2)

Guideline comparison and algorithm (visual): Table 2 and Figure 2 extracted from Mohamed et al. summarize across NCCN/NANETS/ENETS/UK NET guidance when to recommend appendectomy versus RHC and show a post-appendectomy surgical algorithm. (mohamed2022managementofappendix media 6bf50e49, mohamed2022managementofappendix media 58ffb4ea, mohamed2022managementofappendix media 5c304756)

Systemic therapy (advanced disease)

  • For well-differentiated metastatic NENs, the evidence set primarily supports SSTR-based imaging and implies feasibility of SSTR-targeted approaches (SSAs/PRRT) when SSTR-positive; appendiceal-specific systemic trial evidence was not directly retrieved. (mohamed2022managementofappendix pages 4-5)
  • For poorly differentiated NECs, platinum–etoposide is noted as a standard approach in the guideline synthesis. (mohamed2022managementofappendix pages 14-16)

Treatment outcomes and surveillance

  • The 2022 guideline-synthesis review notes that many well-differentiated appendiceal NETs <2 cm with negative margins and limited mesoappendiceal invasion have low recurrence risk and often do not require surveillance. (mohamed2022managementofappendix pages 4-5)
  • A 2025 institutional analysis similarly concluded that for tumors <2 cm, completion hemicolectomy is overtreatment and “postoperative surveillance is unlikely to be of benefit” (quote captured in evidence). (altoubah2025doappendicealneuroendocrine pages 1-2)

MAXO term suggestions (non-exhaustive)

  • Appendectomy; right hemicolectomy; lymphadenectomy (surgical)
  • Contrast-enhanced CT; MRI; somatostatin receptor PET (diagnostic)
  • Somatostatin analogue therapy; peptide receptor radionuclide therapy (PRRT) (advanced disease; where applicable)

13. Prevention

No primary prevention strategies specific to appendiceal NET were supported in the retrieved sources; the dominant theme is incidental detection during appendectomy rather than screening. (mohamed2022managementofappendix pages 1-2)

14. Other species / natural disease

No cross-species naturally occurring appendiceal NET evidence was identified in the retrieved documents. (mohamed2022managementofappendix pages 1-2)

15. Model organisms

No appendiceal-NET-specific animal models, organoids, or cell lines were identified in the retrieved evidence set; any discussion of model systems would require additional targeted searches outside the current corpus. (mohamed2022managementofappendix pages 1-2)

Recent developments (2023–2025 highlights)

  1. Incidence escalation in the US: SEER-based analysis documents a strong rise in aNET incidence (0.03→0.90 per 100,000 person-years, 2000–2017), likely reflecting stage migration and detection. (Nov 2023; https://doi.org/10.1371/journal.pone.0294153) (wang2023incidencetrendsand pages 13-14)
  2. Surgical de-escalation evidence for 1–2 cm tumors: large pooled cohort demonstrates no survival benefit to hemicolectomy and no metachronous metastases after complete resection. (Feb 2023; https://doi.org/10.1016/S1470-2045(22)00750-1) (nesti2023hemicolectomyversusappendectomy pages 5-12)
  3. Reassessment of completion surgery criteria: single-center cohort quantifies potential overtreatment when applying guideline criteria broadly; tumor size >2 cm emerges as the dominant predictor of nodal disease. (Jan 2025; https://doi.org/10.1007/s00423-024-03603-6) (wachter2025retrospectiveanalysisof pages 1-2)
  4. Metastasis rarity and questionable value of surveillance: institutional series suggests stage IV disease is exceptionally rare and usually synchronous; surveillance benefit after resection of small tumors appears minimal. (Jan 2025; https://doi.org/10.6004/jnccn.2024.7069) (altoubah2025doappendicealneuroendocrine pages 1-2)

Clinical trials and real-world studies (selected; clinicaltrials.gov)

  • NCT05919758 (Recruiting): “Value of Right-sided Hemicolectomy for Children With High-risk Neuroendocrine Tumors of the Appendix” (observational; large target enrollment). (clinicaltrials.gov record retrieved in this run) (NCT05919758 chunk 1)
  • NCT02730104 (Completed): “Community-based Neuroendocrine Tumor (NET) Research Study” (observational). (NCT02730104 chunk 1)

Notes on evidence limitations for knowledge-base population

  • Ontology identifiers (MONDO/Orphanet/MeSH/ICD) were not recoverable from retrieved texts; additional targeted retrieval (e.g., MeSH browser, MONDO, Orphanet, ICD-11 MMS) is required.
  • Appendiceal-NET-specific genomics and model organism resources were not present in the current evidence set; these should be populated via targeted molecular studies (e.g., sequencing cohorts) and model-system literature.

Key “direct abstract” quotes captured in this evidence set

  • On management controversy and size thresholds (review): “Simple appendectomy is curative for appendiceal NETs (G1–G2) < 1 cm… whereas RHC… is recommended in tumors ≥ 2 cm…” (May 2023) (andrini2023anupdateon pages 1-3)
  • On incidence and stage migration (registry study): “the annual incidence of appendiceal neuroendocrine tumors (aNETs) increased significantly, from 0.03 to 0.90 per 100,000 person-years…” (Nov 2023) (wang2023incidencetrendsand pages 13-14)
  • On pooled cohort outcomes (study summary evidence): “All metastases were diagnosed synchronously with no tumour-related deaths during the follow-up.” (Feb 2023) (nesti2023hemicolectomyversusappendectomy pages 5-12)

References

  1. (andrini2023anupdateon pages 1-3): Elisa Andrini, Giuseppe Lamberti, Laura Alberici, Claudio Ricci, and Davide Campana. An update on appendiceal neuroendocrine tumors. Current Treatment Options in Oncology, 24:742-756, May 2023. URL: https://doi.org/10.1007/s11864-023-01093-0, doi:10.1007/s11864-023-01093-0. This article has 26 citations and is from a peer-reviewed journal.

  2. (mohamed2022managementofappendix pages 1-2): Amr Mohamed, Sulin Wu, Mohamed Hamid, Amit Mahipal, Sakti Cjakrabarti, David Bajor, J. Eva Selfridge, and Sylvia L. Asa. Management of appendix neuroendocrine neoplasms: insights on the current guidelines. Cancers, 15:295, Dec 2022. URL: https://doi.org/10.3390/cancers15010295, doi:10.3390/cancers15010295. This article has 55 citations.

  3. (nesti2023hemicolectomyversusappendectomy pages 5-12): Cédric Nesti, Konstantin Bräutigam, Marta Benavent, Laura Bernal, Hessa Boharoon, Johan Botling, Antonin Bouroumeau, Iva Brcic, Maximilian Brunner, Guillaume Cadiot, Maria Camara, Emanuel Christ, Thomas Clerici, Ashley K Clift, Hamish Clouston, Lorenzo Cobianchi, Jarosław B Ćwikła, Kosmas Daskalakis, Andrea Frilling, Rocio Garcia-Carbonero, Simona Grozinsky-Glasberg, Jorge Hernando, Valérie Hervieu, Johannes Hofland, Pernille Holmager, Frediano Inzani, Henning Jann, Paula Jimenez-Fonseca, Enes Kaçmaz, Daniel Kaemmerer, Gregory Kaltsas, Branislav Klimacek, Ulrich Knigge, Agnieszka Kolasińska-Ćwikła, Walter Kolb, Beata Kos-Kudła, Catarina Alisa Kunze, Stefania Landolfi, Stefano La Rosa, Carlos López López, Kerstin Lorenz, Maurice Matter, Peter Mazal, Claudia Mestre-Alagarda, Patricia Morales del Burgo, Els J M Nieveen van Dijkum, Kira Oleinikov, Lorenzo A Orci, Francesco Panzuto, Marianne Pavel, Marine Perrier, Henrik Mikael Reims, Guido Rindi, Anja Rinke, Maria Rinzivillo, Xavier Sagaert, Ilker Satiroglu, Andreas Selberherr, Alexander R Siebenhüner, Margot E T Tesselaar, Michael J Thalhammer, Espen Thiis-Evensen, Christos Toumpanakis, Timon Vandamme, José G van den Berg, Alessandro Vanoli, Marie-Louise F van Velthuysen, Chris Verslype, Stephan A Vorburger, Alessandro Lugli, John Ramage, Marcel Zwahlen, Aurel Perren, and Reto M Kaderli. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, europe-wide, pooled cohort study. The Lancet Oncology, 24:187-194, Feb 2023. URL: https://doi.org/10.1016/s1470-2045(22)00750-1, doi:10.1016/s1470-2045(22)00750-1. This article has 90 citations and is from a highest quality peer-reviewed journal.

  4. (mohamed2022managementofappendix pages 2-4): Amr Mohamed, Sulin Wu, Mohamed Hamid, Amit Mahipal, Sakti Cjakrabarti, David Bajor, J. Eva Selfridge, and Sylvia L. Asa. Management of appendix neuroendocrine neoplasms: insights on the current guidelines. Cancers, 15:295, Dec 2022. URL: https://doi.org/10.3390/cancers15010295, doi:10.3390/cancers15010295. This article has 55 citations.

  5. (wang2023incidencetrendsand pages 13-14): Dan Wang, Heming Ge, Yebin Lu, and Xuejun Gong. Incidence trends and survival analysis of appendiceal tumors in the united states: primarily changes in appendiceal neuroendocrine tumors. PLOS ONE, 18:e0294153, Nov 2023. URL: https://doi.org/10.1371/journal.pone.0294153, doi:10.1371/journal.pone.0294153. This article has 31 citations and is from a peer-reviewed journal.

  6. (mohamed2022managementofappendix pages 4-5): Amr Mohamed, Sulin Wu, Mohamed Hamid, Amit Mahipal, Sakti Cjakrabarti, David Bajor, J. Eva Selfridge, and Sylvia L. Asa. Management of appendix neuroendocrine neoplasms: insights on the current guidelines. Cancers, 15:295, Dec 2022. URL: https://doi.org/10.3390/cancers15010295, doi:10.3390/cancers15010295. This article has 55 citations.

  7. (andrini2023anupdateon pages 7-9): Elisa Andrini, Giuseppe Lamberti, Laura Alberici, Claudio Ricci, and Davide Campana. An update on appendiceal neuroendocrine tumors. Current Treatment Options in Oncology, 24:742-756, May 2023. URL: https://doi.org/10.1007/s11864-023-01093-0, doi:10.1007/s11864-023-01093-0. This article has 26 citations and is from a peer-reviewed journal.

  8. (nesti2023hemicolectomyversusappendectomy pages 16-21): Cédric Nesti, Konstantin Bräutigam, Marta Benavent, Laura Bernal, Hessa Boharoon, Johan Botling, Antonin Bouroumeau, Iva Brcic, Maximilian Brunner, Guillaume Cadiot, Maria Camara, Emanuel Christ, Thomas Clerici, Ashley K Clift, Hamish Clouston, Lorenzo Cobianchi, Jarosław B Ćwikła, Kosmas Daskalakis, Andrea Frilling, Rocio Garcia-Carbonero, Simona Grozinsky-Glasberg, Jorge Hernando, Valérie Hervieu, Johannes Hofland, Pernille Holmager, Frediano Inzani, Henning Jann, Paula Jimenez-Fonseca, Enes Kaçmaz, Daniel Kaemmerer, Gregory Kaltsas, Branislav Klimacek, Ulrich Knigge, Agnieszka Kolasińska-Ćwikła, Walter Kolb, Beata Kos-Kudła, Catarina Alisa Kunze, Stefania Landolfi, Stefano La Rosa, Carlos López López, Kerstin Lorenz, Maurice Matter, Peter Mazal, Claudia Mestre-Alagarda, Patricia Morales del Burgo, Els J M Nieveen van Dijkum, Kira Oleinikov, Lorenzo A Orci, Francesco Panzuto, Marianne Pavel, Marine Perrier, Henrik Mikael Reims, Guido Rindi, Anja Rinke, Maria Rinzivillo, Xavier Sagaert, Ilker Satiroglu, Andreas Selberherr, Alexander R Siebenhüner, Margot E T Tesselaar, Michael J Thalhammer, Espen Thiis-Evensen, Christos Toumpanakis, Timon Vandamme, José G van den Berg, Alessandro Vanoli, Marie-Louise F van Velthuysen, Chris Verslype, Stephan A Vorburger, Alessandro Lugli, John Ramage, Marcel Zwahlen, Aurel Perren, and Reto M Kaderli. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, europe-wide, pooled cohort study. The Lancet Oncology, 24:187-194, Feb 2023. URL: https://doi.org/10.1016/s1470-2045(22)00750-1, doi:10.1016/s1470-2045(22)00750-1. This article has 90 citations and is from a highest quality peer-reviewed journal.

  9. (nesti2023hemicolectomyversusappendectomy pages 30-36): Cédric Nesti, Konstantin Bräutigam, Marta Benavent, Laura Bernal, Hessa Boharoon, Johan Botling, Antonin Bouroumeau, Iva Brcic, Maximilian Brunner, Guillaume Cadiot, Maria Camara, Emanuel Christ, Thomas Clerici, Ashley K Clift, Hamish Clouston, Lorenzo Cobianchi, Jarosław B Ćwikła, Kosmas Daskalakis, Andrea Frilling, Rocio Garcia-Carbonero, Simona Grozinsky-Glasberg, Jorge Hernando, Valérie Hervieu, Johannes Hofland, Pernille Holmager, Frediano Inzani, Henning Jann, Paula Jimenez-Fonseca, Enes Kaçmaz, Daniel Kaemmerer, Gregory Kaltsas, Branislav Klimacek, Ulrich Knigge, Agnieszka Kolasińska-Ćwikła, Walter Kolb, Beata Kos-Kudła, Catarina Alisa Kunze, Stefania Landolfi, Stefano La Rosa, Carlos López López, Kerstin Lorenz, Maurice Matter, Peter Mazal, Claudia Mestre-Alagarda, Patricia Morales del Burgo, Els J M Nieveen van Dijkum, Kira Oleinikov, Lorenzo A Orci, Francesco Panzuto, Marianne Pavel, Marine Perrier, Henrik Mikael Reims, Guido Rindi, Anja Rinke, Maria Rinzivillo, Xavier Sagaert, Ilker Satiroglu, Andreas Selberherr, Alexander R Siebenhüner, Margot E T Tesselaar, Michael J Thalhammer, Espen Thiis-Evensen, Christos Toumpanakis, Timon Vandamme, José G van den Berg, Alessandro Vanoli, Marie-Louise F van Velthuysen, Chris Verslype, Stephan A Vorburger, Alessandro Lugli, John Ramage, Marcel Zwahlen, Aurel Perren, and Reto M Kaderli. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, europe-wide, pooled cohort study. The Lancet Oncology, 24:187-194, Feb 2023. URL: https://doi.org/10.1016/s1470-2045(22)00750-1, doi:10.1016/s1470-2045(22)00750-1. This article has 90 citations and is from a highest quality peer-reviewed journal.

  10. (altoubah2025doappendicealneuroendocrine pages 1-2): Taymeyah Al-Toubah, Mintallah Haider, Eleonora Pelle, Maria Grazia Maratta, and Jonathan Strosberg. Do appendiceal neuroendocrine tumors metastasize post appendectomy or right hemicolectomy? Jan 2025. URL: https://doi.org/10.6004/jnccn.2024.7069, doi:10.6004/jnccn.2024.7069. This article has 5 citations and is from a domain leading peer-reviewed journal.

  11. (altoubah2025doappendicealneuroendocrine pages 2-3): Taymeyah Al-Toubah, Mintallah Haider, Eleonora Pelle, Maria Grazia Maratta, and Jonathan Strosberg. Do appendiceal neuroendocrine tumors metastasize post appendectomy or right hemicolectomy? Jan 2025. URL: https://doi.org/10.6004/jnccn.2024.7069, doi:10.6004/jnccn.2024.7069. This article has 5 citations and is from a domain leading peer-reviewed journal.

  12. (altoubah2025doappendicealneuroendocrine pages 3-4): Taymeyah Al-Toubah, Mintallah Haider, Eleonora Pelle, Maria Grazia Maratta, and Jonathan Strosberg. Do appendiceal neuroendocrine tumors metastasize post appendectomy or right hemicolectomy? Jan 2025. URL: https://doi.org/10.6004/jnccn.2024.7069, doi:10.6004/jnccn.2024.7069. This article has 5 citations and is from a domain leading peer-reviewed journal.

  13. (wachter2025retrospectiveanalysisof pages 1-2): Sabine Wächter, Dimitrios Panidis, Moritz Jesinghaus, Anja Rinke, Monika Heinzel-Gutenbrunner, Elisabeth Maurer, and Detlef K. Bartsch. Retrospective analysis of criteria for oncological completion surgery of neuroendocrine tumors of the appendix. Langenbeck's Archives of Surgery, Jan 2025. URL: https://doi.org/10.1007/s00423-024-03603-6, doi:10.1007/s00423-024-03603-6. This article has 1 citations.

  14. (wachter2025retrospectiveanalysisof pages 2-4): Sabine Wächter, Dimitrios Panidis, Moritz Jesinghaus, Anja Rinke, Monika Heinzel-Gutenbrunner, Elisabeth Maurer, and Detlef K. Bartsch. Retrospective analysis of criteria for oncological completion surgery of neuroendocrine tumors of the appendix. Langenbeck's Archives of Surgery, Jan 2025. URL: https://doi.org/10.1007/s00423-024-03603-6, doi:10.1007/s00423-024-03603-6. This article has 1 citations.

  15. (vasile2025neuroendocrinetumorsof pages 3-4): Liviu Vasile, Laurenţiu Augustus Barbu, Gabriel Florin Răzvan Mogoş, Valeriu Şurlin, Ionică Daniel Vîlcea, Liliana Cercelaru, Stelian Ştefăniţă Mogoantă, Nicolae-Dragoş Mărgăritescu, and Victor Nimigean. Neuroendocrine tumors of the appendix: a comprehensive review of the literature and case presentation. Romanian Journal of Morphology and Embryology, 66:269-278, Aug 2025. URL: https://doi.org/10.47162/rjme.66.2.01, doi:10.47162/rjme.66.2.01. This article has 4 citations and is from a peer-reviewed journal.

  16. (kim2025appendicealneuroendocrinetumor pages 4-6): YESEUL KIM, YOU-NA SUNG, ANNA THERESE DATUIN, INHO JANG, and JONGMIN SIM. Appendiceal neuroendocrine tumor: clinicopathologic characteristics of six cases and review of the literature. In Vivo, 39:559-565, Dec 2025. URL: https://doi.org/10.21873/invivo.13860, doi:10.21873/invivo.13860. This article has 4 citations and is from a peer-reviewed journal.

  17. (mohamed2022managementofappendix media 6bf50e49): Amr Mohamed, Sulin Wu, Mohamed Hamid, Amit Mahipal, Sakti Cjakrabarti, David Bajor, J. Eva Selfridge, and Sylvia L. Asa. Management of appendix neuroendocrine neoplasms: insights on the current guidelines. Cancers, 15:295, Dec 2022. URL: https://doi.org/10.3390/cancers15010295, doi:10.3390/cancers15010295. This article has 55 citations.

  18. (mohamed2022managementofappendix media 58ffb4ea): Amr Mohamed, Sulin Wu, Mohamed Hamid, Amit Mahipal, Sakti Cjakrabarti, David Bajor, J. Eva Selfridge, and Sylvia L. Asa. Management of appendix neuroendocrine neoplasms: insights on the current guidelines. Cancers, 15:295, Dec 2022. URL: https://doi.org/10.3390/cancers15010295, doi:10.3390/cancers15010295. This article has 55 citations.

  19. (mohamed2022managementofappendix media 5c304756): Amr Mohamed, Sulin Wu, Mohamed Hamid, Amit Mahipal, Sakti Cjakrabarti, David Bajor, J. Eva Selfridge, and Sylvia L. Asa. Management of appendix neuroendocrine neoplasms: insights on the current guidelines. Cancers, 15:295, Dec 2022. URL: https://doi.org/10.3390/cancers15010295, doi:10.3390/cancers15010295. This article has 55 citations.

  20. (mohamed2022managementofappendix pages 14-16): Amr Mohamed, Sulin Wu, Mohamed Hamid, Amit Mahipal, Sakti Cjakrabarti, David Bajor, J. Eva Selfridge, and Sylvia L. Asa. Management of appendix neuroendocrine neoplasms: insights on the current guidelines. Cancers, 15:295, Dec 2022. URL: https://doi.org/10.3390/cancers15010295, doi:10.3390/cancers15010295. This article has 55 citations.

Artifacts